![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Prestige Wins European Review for Breast, Esophageal Cancer Biosimilar
Prestige Wins European Review for Breast, Esophageal Cancer Biosimilar
June 11, 2019
European regulators have agreed to review Prestige BioPharma’s application for a biosimilar to treat breast and esophageal cancers, the Singapore-based company announced.
HD201 is Prestige’s lead candidate as a biosimilar to Herceptin (trastuzumab), which has already been approved for HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma and HER2-overexpress breast cancer.
Herceptin has been a blockbuster for Roche, with nearly $3 billion in U.S. sales last year alone. Its patent expires in a couple of weeks. Prestige says it has eight other biosimilars/biologics in its development pipeline.
Upcoming Events
-
21Oct